Reducing Sample Clauses

Reducing. “NEW USE PATENTS” There has been an increase in the number of “new use” patents that have been filed in the past few years. New use patent provisions allow companies to apply for a new patent for each “new use” of a product. Un- der this provision, a drug that is currently used to treat AIDS could receive a new 20-year patent monopoly if it were found to be effective against cancer. Countries can include provisions in their patent legislations that prevent new use patents unless there is an innovative step involved. 32 A series of bilateral negotiations was at the time established between Brazil, India, South Africa and China in view of the technical competence of the four countries in the areas of research, development and manufacture of a range of inputs for prevention and treatment of HIV/AIDS. Subsequently a number of other developing countries expressed interest in the initiative. The Network has met twice so far and its third meeting was just completed in Cuba in May 2006. For more information on the network, xxxx.xxx as UNDP has served as an observer in the meetings since the Network’s inception. 33 These measures are explained in more detail below- such as reducing new use and data exclusivity 7: OPTIONS OUTSIDE TRIPS ‘PRE-GRANT OPPOSITION’ PROVISON UNDER THE INDIAN PATENT ACT 2005 Often due to the volume of patent applications, patent examiners often miss information related to the patent application under consideration- e.g. if it is just a small improvement over an old drug. If attention is brought to information that shows that the patent application is for a ‘derivative’ or a ‘new use’ of a known drug, the possibility of invalid patents being granted is reduced. Anyone can bring such information to the attention of the patent controller through the pre-grant opposition process (as provided under Section 25 of the Indian Patents Act), Generic companies have already filed a number of pre-grant oppositions. In addition to companies, patient groups and public interest organizations are also working to oppose patent applications for essential drugs. Most of the opposition filings and movements have been mobilized by CSOs and groups of people living with HIV/AIDS . On January 2006, the Indian Patent office rejected Novartis’ patent application for its anti cancer drug Gleevec- on the grounds ‘new form of a known substance. The rejection was a major victory for Cancer patient Aid Association of India and some generic companies that had submitted a pr...
Sample 1Sample 2
Reducing barriers to individual stability, health and independence.
Sample 1
Reducing increasing, consolidating, sub-dividing or converting any of SCH’s share capital or reserves or in any way altering the rights attaching to any class of Shares.
Sample 1
Reducing. IB&C shall reduce the client's scope of certification to exclude the parts not meeting the requirements, when the client has persistently or seriously failed to meet the certification requirements of those parts of the scope of certification. Any such reduction shall be in line with the requirements of the standard used for certification. IB&C’s decision on reducing the scope of certification shall be communicated to the client, in writing, through letter IB&CF45.0. Unless otherwise agreed in writing, the Client shall be entitled to terminate the Contract at any time by giving not less than Ninety days notice in writing to IB&C . If the Client terminates the Contract (other than by reason of default by International Benchmarking & Certifications in its obligations) International Benchmarking & Certifications shall be entitled to charge the Client reasonable fees at agreed contract rates and expenses in respect to work carried out by it for the Client prior to termination.
Sample 1
Reducing. Grindability, HGI D409 [*](3) [*](3) [*](3) -----------------------------------------------------------------------------------------------------------------------------------
Sample 1

Related to Reducing

  • Undercharging (a) If we have undercharged you, we may recover the undercharged amount from you. If we recover an undercharged amount from you:

  • Reduction A. No regular employee or limited-term regular employee shall be reduced to a position in a lower class for reasons of unsatisfactory performance or physical disability except for reasonable cause.

  • No Reduction The Guaranteed Debt may not be reduced, discharged, or released because or by reason of any existing or future offset, claim, or defense (except for the defense of complete and final payment of the Guaranteed Debt) of Borrower or any other obligor against Administrative Agent or any Lender or against payment of the Guaranteed Debt, whether that offset, claim, or defense arises in connection with the Guaranteed Debt or otherwise. Those claims and defenses include, without limitation, failure of consideration, breach of warranty, fraud, bankruptcy, incapacity/infancy, statute of limitations, lender liability, accord and satisfaction, usury, forged signatures, mistake, impossibility, frustration of purpose, and unconscionability.

  • Increase (a) The Company may by giving prior notice to the Agent by no later than the date falling 20 Business Days after the effective date of a cancellation of:

  • Maximum Accumulation Maximum accumulation amounts apply only to the amount of annual leave that may be carried over from one leave year to the next, and do not limit accumulated leave balances during the leave year.

  • Underutilization Underutilization of Interconnection Trunks and facilities exists when provisioned capacity of trunks in service for more than six (6) months is greater than the current need. This over-provisioning is an inefficient deployment and use of network resources and results in unnecessary costs. Those situations where more capacity exists than actual usage will be handled in the following manner:

  • Reductions (a) If a Lender or a Participant is subject to an applicable withholding tax, Agent (or, in the case of a Participant, the Lender granting the participation) may withhold from any payment to such Lender or such Participant an amount equivalent to the applicable withholding tax. If the forms or other documentation required by Section 16.2(a) or 16.2(c) are not delivered to Agent (or, in the case of a Participant, to the Lender granting the participation), then Agent (or, in the case of a Participant, to the Lender granting the participation) may withhold from any payment to such Lender or such Participant not providing such forms or other documentation an amount equivalent to the applicable withholding tax.

  • Maximum Percentage A holder of a Warrant may notify the Company in writing in the event it elects to be subject to the provisions contained in this subsection 3.3.5; however, no holder of a Warrant shall be subject to this subsection 3.3.5 unless he, she or it makes such election. If the election is made by a holder, the Warrant Agent shall not effect the exercise of the holder’s Warrant, and such holder shall not have the right to exercise such Warrant, to the extent that after giving effect to such exercise, such person (together with such person’s affiliates), to the Warrant Agent’s actual knowledge, would beneficially own in excess of 4.9% or 9.8% (or such other amount as a holder may specify)(the “Maximum Percentage”) of the shares of Common Stock outstanding immediately after giving effect to such exercise. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by such person and its affiliates shall include the number of shares of Common Stock issuable upon exercise of the Warrant with respect to which the determination of such sentence is being made, but shall exclude shares of Common Stock that would be issuable upon (x) exercise of the remaining, unexercised portion of the Warrant beneficially owned by such person and its affiliates and (y) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company beneficially owned by such person and its affiliates (including, without limitation, any convertible notes or convertible preferred stock or warrants) subject to a limitation on conversion or exercise analogous to the limitation contained herein. Except as set forth in the preceding sentence, for purposes of this paragraph, beneficial ownership shall be calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). For purposes of the Warrant, in determining the number of outstanding shares of Common Stock, the holder may rely on the number of outstanding shares of Common Stock as reflected in (1) the Company’s most recent annual report on Form 10-K, quarterly report on Form 10-Q, current report on Form 8-K or other public filing with the Commission as the case may be, (2) a more recent public announcement by the Company or (3) any other notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. For any reason at any time, upon the written request of the holder of the Warrant, the Company shall, within two (2) Business Days, confirm orally and in writing to such holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of equity securities of the Company by the holder and its affiliates since the date as of which such number of outstanding shares of Common Stock was reported. By written notice to the Company, the holder of a Warrant may from time to time increase or decrease the Maximum Percentage applicable to such holder to any other percentage specified in such notice; provided, however, that any such increase shall not be effective until the sixty-first (61st) day after such notice is delivered to the Company.

  • Increases Seller shall provide the Administrative Agent with at least two (2) Business Days’ prior notice in a form set forth as Exhibit II hereto of each Incremental Purchase (a “Purchase Notice”). Each Purchase Notice shall be subject to Section 6.2 and, except as set forth below, shall be irrevocable and shall specify the requested Purchase Price (which shall not be less than $1,000,000) and date of purchase and, in the case of an Incremental Purchase to be funded by the Financial Institutions, the requested Discount Rate and Tranche Period. Following receipt of a Purchase Notice, the Administrative Agent will determine whether Company agrees to make the purchase. If Company declines to make a proposed purchase, Seller may cancel the Purchase Notice or, in the absence of such a cancellation, the Incremental Purchase of the Purchaser Interest will be made by the Financial Institutions. On the date of each Incremental Purchase, upon satisfaction of the applicable conditions precedent set forth in Article VI, Company or the Financial Institutions, as applicable, shall initiate a wire transfer of immediately available funds to the Facility Account, no later than 12:00 noon (Chicago time), an amount equal to (i) in the case of Company, the aggregate Purchase Price of the Purchaser Interests Company is then purchasing or (ii) in the case of a Financial Institution, such Financial Institution’s Pro Rata Share of the aggregate Purchase Price of the Purchaser Interests the Financial Institutions are purchasing. There may not be more than four (4) Incremental Purchases during any calendar month.

  • Utilization This agreement does not constitute, in any way, a guarantee of utilization of the provider's services.